CSL News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

21.12.23	CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster (PR Newswire)
14.12.23	CSL's Garadacimab, a First-in-Class Factor XIIa Inhibitor, Receives FDA and EMA Filing Acceptance (PR Newswire)
12.12.23	CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in Peopl... (PR Newswire)
28.11.23	Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults (PR Newswire)
24.11.23	Iron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment (PR Newswire)
27.10.23	CSL and uniQure Win 2023 Prix Galien USA Award (PR Newswire)
11.10.23	New Data Presented at IDWeek 2023 Demonstrates Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines (PR Newswire)
19.09.23	CSL Seqirus Presents Real-World Evidence at ESWI Demonstrating the Impact of Influenza Vaccination Campaigns to Help Protect People and Healthcare Systems (PR Newswire)
28.08.23	CSL Seqirus Announces Third U.S. Government Award in Relation to Influenza A(H5N8) Candidate Vaccine (PR Newswire)
28.08.23	Ferinject® granted upgraded recommendations in 2023 ESC heart failure guidelines (PR Newswire)
17.08.23	CSL Appoints Jeffrey Ball as First Chief Sustainability Officer (PR Newswire)
17.07.23	CSL Seqirus Begins Shipping Portfolio of Innovative Influenza Vaccines for the 2023/24 U.S. Season (PR Newswire)
20.06.23	CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B (PR Newswire)
05.06.23	Injectafer® approved in the U.S. for the treatment of iron deficiency in patients with heart failure (PR Newswire)
18.05.23	Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus (PR Newswire)
02.05.23	Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis (PR Newswire)
18.04.23	CSL Behring Receives FDA Approval for Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 50mL Prefilled Syringe (PR Newswire)
28.03.23	Tavneos® (avacopan) included in updated EULAR recommendations for the management of AAV (PR Newswire)
27.03.23	CSL Opens New, State-of-the-Art Vaccine Research and Development Facility in Waltham, Massachusetts (PR Newswire)
01.03.23	The Lancet Publishes Pivotal Phase 3 Data on CSL's First-in-Class Garadacimab for HAE (PR Newswire)
26.02.23	CSL's Phase 3 Study Shows First-In-Class Garadacimab Provides Patients with Significant HAE Attack Prevention with Monthly Dosing (PR Newswire)
23.02.23	CSL's HOPE-B Data Published in the New England Journal of Medicine, Demonstrating Efficacy and Durability of HEMGENIX® (etranacogene dezaparvovec-drlb) (PR Newswire)
21.02.23	Biotech Leader CSL Again Named Among America's Best Employers by Forbes (PR Newswire)
20.02.23	First Gene Therapy for Hemophilia B, CSL's HEMGENIX®, Approved by the European Commission (PR Newswire)
12.12.22	CSL Announces Next CEO & Managing Director (PR Newswire)
12.12.22	CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics (PR Newswire)
10.12.22	CSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Tr... (PR Newswire)
22.11.22	U.S. Food and Drug Administration approves CSL's HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B (PR Newswire)
02.11.22	Next-Generation mRNA, Gene Therapy, Plasma Products, Monoclonal Antibodies, and Recent Acquisitions and Collaborations Highlight CSL R&D Day 2022 (PR Newswire)
01.11.22	CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology (PR Newswire)
06.10.22	CSL Seqirus Announces U.S. Government Award to Manufacture and Clinically Assess Influenza A(H5N8) Pre-Pandemic Vaccine (PR Newswire)
05.10.22	CSL Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates (PR Newswire)
26.09.22	New Data at OPTIONS XI Conference Highlight Burden of Seasonal Influenza on Health Systems and the Need for Increased Vaccination Rates (PR Newswire)
26.09.22	New Real-World Data Presented at OPTIONS XI Show Cell-Based and MF59®-Adjuvanted Influenza Vaccines Can Reduce the Burden of Seasonal Influenza on Hospitals and Health Systems (PR Newswire)
13.09.22	CSL presents new research and development center in Marburg, Germany (PR Newswire)
13.09.22	CSL Seqirus to Highlight Commitment to Influenza Protection with More than 20 Data Presentations at OPTIONS XI (PR Newswire)
08.09.22	CSL Plasma Provides Free Flu Vaccines to U.S. Plasma Donors (PR Newswire)
17.08.22	CSL Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE) (PR Newswire)
17.08.22	CSL announces carbon emissions reduction targets (PR Newswire)
10.08.22	CSL LAUNCHES NEW UNIFIED GLOBAL BRAND IDENTITY (PR Newswire)
04.08.22	CSL Plasma Reimagines Donor Experience With First Donations Completed on Innovative Plasma Collection Technology (PR Newswire)
11.07.22	Seqirus Begins Shipping Portfolio of Innovative Influenza Vaccines for the 2022/23 U.S. Season (PR Newswire)
22.06.22	CDC Advisory Committee Includes FLUAD® QUADRIVALENT as a Preferentially Recommended Influenza Vaccine for Adults 65 and Older (PR Newswire)
09.06.22	Acclaimed Photographer Rankin and CSL Behring Team Up to Launch 'Portraits of Progress', an Exhibition Chronicling the Past, Present and Future of Life with Hemophilia (PR Newswire)
06.06.22	Seqirus Completes $156 Million Expansion to Holly Springs Manufacturing Facility, Optimizing Global Manufacturing Capabilities for Seasonal and Pandemic Influenza Vaccines (PR Newswire)
02.06.22	Seqirus' Holly Springs Manufacturing Facility Designated by U.S. Government as Pandemic Ready (PR Newswire)
24.05.22	FDA Accepts CSL Behring's Biologics License Application for Etranacogene Dezaparvovec for Priority Review (PR Newswire)
11.05.22	Walter Charles Named Senior Vice President and General Manager of CSL Plasma (PR Newswire)
28.04.22	CSL Behring Donates 500 Million International Units of Coagulation Factor Replacement Therapy to the World Federation of Hemophilia Humanitarian Aid Program to Help Those Living with Bleeding Diso... (PR Newswire)
28.03.22	European Medicines Agency Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with Hemophilia B (PR Newswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Alcon	77.62	1.81 %	K V
CieFinRichemont	122.35	0.99 %	K V
Lonza Grp	531.00	0.84 %	K V
Zurich Insur Gr	553.00	0.18 %	K V
Novartis	91.93	0.00 %	K V
ABB	49.54	-0.84 %	K V
Swisscom	504.00	-0.98 %	K V
Sika	228.60	-1.12 %	K V
Holcim	88.42	-1.51 %	K V
UBS Group	27.76	-2.08 %	K V